Advertisement

Topics

Replicon Technologies Incorporated Company Profile

03:40 EDT 20th September 2017 | BioPortfolio

Replicon Technologies, Inc. (RTI) is an emerging biotechnology company focused on the use of replicons, non-replicating RNA viral particles, for the treatment of patients with cancer. RTI is founded on research and development performed at the University of Alabama at Birmingham (UAB), and supported by competitive grants from the National Institutes of Health, the Department of Defense, and SBIR grants from the National Cancer Institute.

RTI’s replicons are oncolytic in a broad range of cancers, can cross the blood brain barrier, and efficiently diffuse through CNS tissue to sites of metastases. Replicons are highly selective for tumors due to up-regulation of the poliovirus receptor (CD-155) on cancer cells. Product development is focused on treatment of patients with primary brain cancers and metastases of cancers to the CNS, an area of cancer treatment for which replicons are uniquely suited due to their natural tropism for CNS tissues. The CNS is an area where current therapeutic alternatives of chemotherapy and radiation are minimally effective and cause excessive morbidity. Moreover, there are few, if any, viable new therapies in development for the specialized area of treating brain metastases or cancers to the CNS.

Location

828 Eastbrook Court
Danville
CA
94505-1206
United States of America

Contact

Phone: (925) 736 1863
Fax: (925) 736 5910
Email: DCAnsardi@replicontechnologies.com


News Articles [424 Associated News Articles listed on BioPortfolio]

Advanced Enzymes acquires evoxx

The industrial biotechnology company evoxx technologies GmbH has become a part of specialty biotech company Advanced Enzyme Technologies Limited. Both companies announced that they have entered into a...

Partnership agreement signed to combine epigenetics technologies

A partnership agreement has been entered into by Cambridge Epigenetix (CEGX) and NuGEN Technologies to cover the manufacture and integration of technologies for epigenetic research.

Agilent acquires Cobalt, expanding value for pharma and biopharma

Specialist in analytical laboratory technologies, Agilent Technologies, has acquired Cobalt Light Systems, which develops products and technologies for non-invasive, through-barrier chemical analysis ...

DBV Technologies: DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors

Press Release Montrouge, France, June 15, 2017 DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Mar...

AMS Technologies Extends Design Services with Acquisition of Elforlight

Acquisition strengthens company’s competence and expertise for solving the most challenging photonics applications  AMS Technologies, Europe’s leading solution provider and distributo...

Palatin Technologies: Lust auf mehr Lust statt Frust

Weitere Kursgewinne sind vorprogrammiert bei Palatin Technologies (US6960774031). Die Bodenbildung laut Charts im Artikel Palatin Technologies: Kurvenreicher Lustgewinn durch Ausdauer ist tatsächl...

Reviewing Flamel Technologies

Flamel Technologies and Acura Pharmaceuticals are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitabiliy,...

DBV Technologies Annonce les Résultats de son Assemblée Générale Mixte 2017

DBV Technologies — Thursday, June 15th 2017 at 8:30pm UTC Informations Réglementées Montrouge, France, le 15 juin 2017, 22h30 CEST DBV Technologies Annonce les Résultats de son Assemblée Gé...

PubMed Articles [444 Associated PubMed Articles listed on BioPortfolio]

Development of a stable Japanese encephalitis virus replicon cell line for antiviral screening.

Japanese encephalitis virus (JEV), an important pathogen in Eastern and Southern Asia and the Pacific, has spread to Australia and other territories in recent years. Although the vaccine for JEV has b...

A self-perpetuating repressive state of a viral replication protein blocks superinfection by the same virus.

Diverse animal and plant viruses block the re-infection of host cells by the same or highly similar viruses through superinfection exclusion (SIE), a widely observed, yet poorly understood phenomenon....

Advanced technologies for the remediation of pesticide-contaminated soils.

The occurrence of pesticides in soil has become a highly significant environmental problem, which has been increased by the vast use of pesticides worldwide and the absence of remediation technologies...

Enhancing the Gaming Experience Using 3D Spatial User Interface Technologies.

Three-dimensional (3D) spatial user interface technologies have the potential to make games more immersive and engaging and thus provide a better user experience. Although technologies such as stereos...

Clonal diversity of extended-spectrum beta-lactamase producing Escherichia coli isolates in fecal samples of wild animals.

The clonal diversity of extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli isolates from nine different species of wild animals from distinct regions of Portugal and Spain and their cont...

Clinical Trials [311 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

AVX601, a bivalent alphavirus replicon vaccine expressing three CMV proteins (gB, pp65 and IE1) is a candidate vaccine against cytomegalovirus (CMV). The objectives of this Phase 1 study ...

A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

AVX502, an alphavirus replicon vaccine expressing an influenza HA protein, is a candidate vaccine against influenza. The objectives of this Phase 1 study are to test the safety of the vac...

Application of Monitoring and Intervention Technologies in Suboptimal Health Status

The purpose of this study is to use monitoring and intervention technologies in suboptimal health status in a general population in China and evaluate the effectiveness of these technologi...

Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording

The PulmoTrack® 2010 with WIM-PC™ Technologies device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. This study was designed in order t...

Objective Functional Outcome Measures in Orthopedic Surgery Using Advanced Tracking Technologies

The proposed project will address the measurement and ramifications of out-of-home mobility problems in various orthopedic disorders in an innovative way, using advanced tracking technolog...

Companies [1259 Associated Companies listed on BioPortfolio]

Replicon Corporate Finance Oy/Ltd

Replicon is privately held, independent investment banking service company located in Helsinki, Finland. We provide first-class corporate finance and strategic advisory to our clients. Our range of ex...

Replicon Technologies Incorporated

Replicon Technologies, Inc. (RTI) is an emerging biotechnology company focused on the use of replicons, non-replicating RNA viral particles, for the treatment of patients with cancer. RTI is founded ...

Pharmapraxis

Founded in 2008 by the Axis Biotec Brasil™ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....

PRAECIS PHARMACEUTICALS INCORPORATED

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...

SQI Diagnostics Inc.

SQI Diagnostics is a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprieta...

More Information about "Replicon Technologies Incorporated" on BioPortfolio

We have published hundreds of Replicon Technologies Incorporated news stories on BioPortfolio along with dozens of Replicon Technologies Incorporated Clinical Trials and PubMed Articles about Replicon Technologies Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Replicon Technologies Incorporated Companies in our database. You can also find out about relevant Replicon Technologies Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record